Group items tagged

To provide a portable access of Pharmacy Support and Advice Service to pharmacists and technicians, the National Pharmacy Association (NPA) has launched an 'Associate Pharmacist' subscription. The service, comprising priority news-feed and email alerts, also includes NPA Learn - the association's Learning and Development hub. The offering to associates includes an annual online flu refresher or discounted full face-to-face vaccination training programme. NPA director of membership, Simon Tebbutt, said: "Associate Pharmacist is an offer to individuals, not to pharmacy businesses. We find that many pharmacists and technicians come into contact with NPA resources and like them, experiencing their quality as they move from pharmacy to pharmacy, either as a locum or as part of their career-building.

Pharmacists are a vital member of the multidisciplinary team (MDT) supporting older people to manage their pain. The pharmacist is uniquely positioned to holistically review drug interactions and potential risks associated with each patient's medication and has the expertise to suggest alternative treatment options to reduce the risks associated with polypharmacy or unwanted side effects caused by other medications. Chronic pain The International Association for the Study of Pain defines pain as an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage. Although universally experienced by everyone, the perception of pain is a deeply personal experience influenced by biological, psychological, and social factors, and constitutes an essential behavioural feedback mechanism aimed at protecting us from harm. Pain may be perceived as either acute or chronic. Chronic pain, defined as pain that persists longer than the normal healing time, constitutes a substantial healthcare burden, affecting approximately 20 per cent of people worldwide and accounts for 15-20 per cent of physician consultations. Chronic pain is often associated with disrupted mood and sleep, substance misuse and other chronic conditions. Additionally, comorbidities of chronic pain may also lead to complex medication regimens that increase the risks of adverse drug interactions and unwanted side effects.

The UK government will lay legislation today (13 December 2023) to allow the General Medical Council (GMC) to begin the process of regulating medical associates to expand their roles in the NHS. This will support plans to reduce pressure on doctors and GPs and improve access for patients, the Department of Health and Social Care (DHSC) said. Physician associates (PAs) and anaesthesia associates (AAs) will have the same levels of regulatory oversight and accountability as doctors and other regulated healthcare professionals once the regulations come into force, which is expected at the end of 2024. The GMC will design and deliver detailed regulatory processes for registration, education, standards and fitness to practise for both professions.

The Association of Independent Multiple Pharmacies (AIMp) has changed its name to the Independent Pharmacies Association (IPA). AIMp, now IPA, stated that rebranding was prompted by the demand from independent community pharmacists for an association that properly represents their interests. The membership of the Independent Pharmacies Association will not be restricted to pharmacy owners with multiple branches, as was the case with AIMp, but will be open to all independents, it announced today (Tuesday). It believes that the switch will "provide a clearer identity and afford a strong voice to the thousands of independent pharmacies in England and Wales." Furthermore, the IPA noted that it will not primarily function as an insurance organisation with membership attached, but it will be "fighting for and representing its members across all fronts."

The UK GDP Association has been established as a non-profit organisation, operating as a Community Interest Company (CIC), with a focus on providing a broader support network, particularly for small and medium business enterprises and pharmacy wholesalers. In addition to delivering commercially viable Good Distribution Practice (GDP) consultancy services for simple models with smaller budgets, the association aims to function as a networking platform for Responsible Persons in the UK. As members of the association, companies and individuals can gain multiple benefits that will add value to their business through access to knowledge, discounted training, consultancy services, audit and inspection support, as well as resources like document templates for risk assessments, CAPA, deviations, and more. Moreover, members can enjoy the benefit of a like-minded support network via a dedicated GDP community hub, providing a platform for discussions, seeking advice, and fostering new relationships. "Our mission is to ensure that patient safety, GDP compliance, and excellent quality is paramount in all organisations, regardless of budget," the company said.

The National Pharmacy Association (NPA) has appointed Paul Rees MBE as its new Chief Executive, with his role commencing on November 27th. Rees, currently serving as the Chief Executive of the Royal College of Psychiatrists and having held various roles throughout his career, will succeed Mark Lyonette, who is retiring, NPA said in a statement. "We anticipate Paul joining the NPA after a thorough recruitment process affirmed his suitability," said Nick Kaye, Chair of NPA. "Throughout his career, including his role at the Royal College of Psychiatrists, he has made a significant impact and achieved concrete changes in healthcare and society. I would also like to express my appreciation to Mark for his work as Chief Executive since 2018. He still has important tasks to complete at the NPA before his retirement." Rees has also held key positions at prominent organisations, including the Ramblers Association, National Housing Federation, Charities Aid Foundation, Association of University Teachers, and the , besides being the Head of Communications at the Home Office.

Community Pharmacy England, Company Chemists Association, and the National Pharmacy Association have all expressed their disappointment at a recent press statement made by Dr Leyla Hannbeck, Chief Executive of the Association of Independent Multiple Pharmacies. The CPE, CCA and NPA refuted AIMp's claim that pharmacy bodies operate independently, emphasising the importance of employing various channels and strategies to shape public policy. "It makes sense to use a variety of channels and tactics to influence public policy," NPA, CPE and CCA said in a joint statement issued on Wednesday (August 13). "Limiting our work to just one Parliamentary channel would be naive and do a disservice to pharmacy owners." On Aug. 12, AIMp highlighted that a lack of cohesion was one of the contributing factors to the sector's difficulty in gaining wider attention. Dr. Hannbeck argued that it's counterproductive for each pharmacy organisation to maintain its own manifesto, essentially a lengthy wish-list that is often unrealistic and unattainable. "This can conveniently allow those in power to easily employ a divide-and-conquer strategy," she said.

The community pharmacy bodies, along with England's largest pharmacy chains, have urged the Prime Minister, Rishi Sunak to resolve fund and workforce crisis in the sector. In the joint letter the Chief Executives of Association of Independent Multiple Pharmacies (AIMp), Company Chemists' Association (CCA), National Pharmacy Association (NPA) and Pharmaceutical Services Negotiating Committee (PSNC), along with Boots, Lloydspharmacy, Well and Rowlands Pharmacy, said they are pleased to see Government now recognising the key role that community pharmacy' could have in alleviating the strain on other NHS services. However, the associations also warn that although the sector is ready to support, 'this will not be possible unless pharmacy is properly funded.' Janet Morrison, PSNC Chief Executive, said: "The Prime Minister should also know that community pharmacies are also facing a crisis. They need sustainable investment, urgently, if we are to avoid devasting consequences for pharmacies and for their patients." The letter calls on Government to help pharmacy to resolve the funding, workforce and capacity issues engulfing the sector. It said: "Community pharmacies are in crisis and after 7 years of 30% funding cuts have reached their limit."

The Association of Independent Multiple Pharmacies (AIMp) and senior official of NHS Property Services (NHSPS) had a meeting on August 18 to review the rent policy for health centre pharmacies. Earlier, the association had sent a letter to NHSPS that was signed by pharmacies from across the sector, including single independents, pharmacy groups and members of the Company Chemists' Association. The letter outlined concerns about rent reviews and the impact of it on the co-located health centre pharmacies. Dr Leyla Hannbeck, CEO of AIMp, said: "We outlined that whilst in the past, the norm established by the industry, was to base rents for co-located pharmacies primarily based on patient list size, (and taking account of a few other factors), the industry now needs to revise the basis on which rents are determined for co-located pharmacies." The association, on behalf of the pharmacy sector, met the CEO of NHSPS and two of their senior directors (director or property management and their finance director).

The British Generic Manufacturers Association (BGMA) has published a positioning paper which sets out the objectives that need to be delivered through the next Voluntary Pricing and Access Scheme (VPAS) on Thursday (15 June). The paper details how a financially sustainable VPAS can support widened medicines access to patients. VPAS is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1% but for 2023 it has soared to 26.5%. Last year, the association had raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. "The rocketing rate is in large part due to the growth in spend in on-patent medicines since 2019. Looking at the four completed years of the current VPAS scheme, data shows that the average annual growth rate for on-patent medicine sales value from 2019-22 was 18% compared to just 2% for off-patent products," said the association.

The Association of Independent Multiple Pharmacies (AIMP)'s members are not going to abandon the dosettes boxes, the association has announced. Instead, it insisted that this service should be properly funded. The association has emphasised on the importance of the service provided by pharmacists to elderly patients living independently. Dr Leyla Hannbeck, chief executive of AIMP, said it was vital that patients for whom this service is suitable can continue accessing it and that it is properly funded. Blister pack trays or dosettes assist thousands of people across the UK in living independently and remaining in their own homes for longer. "This is largely attributable to the care and professionalism shown by local pharmacies," said Hannbeck. "Our members, as independent family-owned pharmacies, are not going to abandon this service for patients."

The Pharmacists' Defence Association (PDA) says the pharmacy regulator should maintain a two-year post qualification eligibility criteria, in addition to the qualitative measures being introduced which would be in the best interest of patient safety, before a pharmacist is allowed to commence an IP course. The association was responding to an announcement by the GPhC's move to scrap the two year requirement for Independent Prescribing (IP) course. "The PDA accepts that the qualitative approach could mean greater individual consideration of potential IP course candidates and the two-year measure could have sometimes been a blunt tool. However, the PDA is already seeing cases of patient harm and allegations around fitness to practice arising from IP," the association said. The association also said that it supports individual pharmacists with near misses, as well as actual incidents, giving the organisation possibly the most comprehensive understanding of risk. Frontline pharmacists also recognise these issues and in a survey of over 1,000 pharmacists undertaken by the PDA in late 2021, of those who had 2+ years' experience of practice and who were already independent prescribers, 90 per cent said the qualifying period should be two years or more.

The National Pharmacy Association (NPA) has announced the retirement of its Chief Executive, Mark Lyonette. Mark will retire in 2024. The association has announced his retirement well in advance so that the Board can start work with a leading recruitment agency to search for the new Chief Executive. "The Board is keen to build on the strong foundations established and ensure there is a seamless transition and minimum disruption to the business once the new Chief Executive is in post," said the association. Mark said: "After five years at the NPA and 40 years working for and leading national membership organisations, I am looking forward to living a different life. "I am pleased that in the time that I have been with the NPA we have grown both the membership and customer base and created a profitable, stable membership organisation. "Alongside our NPA Insurance company, the association is well set to help members face the future. "Meanwhile there is much to do to ensure that 2023 is another good year in terms of the NPA delivering consistently for members. The process of changing Chief Executive won't deflect us from our vital work."

The Association of Independent Multiple Pharmacies (AIMp) has called upon all pharmacy organisations to unite and collectively represent the sector. While underlining the need for the sector to adopt a straightforward manifesto that can be presented to the public, politicians, and decision-makers, the association also advocated for a revitalisation of the 'Save Our Pharmacies' campaign, injecting it with renewed energy and a stronger sense of purpose. AIMp pointed out that a lack of cohesion is one of the factors contributing to the sector's struggle in gaining attention. "The current trajectory of community pharmacy is unsustainable," said Dr. Leyla Hannbeck, Chief Executive of AIMp. "To tackle the significant challenges ahead, we must work together cohesively. The most effective approach is to actively engage with Parliament, leveraging politicians from across the political spectrum to advocate for our cause." Meanwhile, the association urged various pharmacy bodies to unite in support of the Pharmacy All Party Parliamentary Group (APPG) to enhance its effectiveness and broaden its influence, rather than working independently.

The General Pharmaceutical Council (GPhC) recently issued a public apology after they mistakenly referred to pharmacy technicians as 'pharmacist technicians' in a council paper. It has also written a letter of apology to the President of the Association of Pharmacy Technicians (APTUK) for the error they made. Meanwhile, the Pharmacists' Defence Association (PDA) has raised concern about an equally worrying trend in which pharmacists are being referred to by the GPhC and others as 'pharmacy professionals', a term that is also used for pharmacy technicians. The association said this creates confusion in the minds of the public about the two roles and responsibilities, which are very different, as well as have impact upon the workplace.

The National Pharmacy Association (NPA) Board has elected 14 Board members on Friday (30 March) that will govern the association for next two years. Four new Board members have been elected while five previous members left the Board after serving their terms. The period April 2023 to March 2025 will see the completion of the transition to the new Board structure. The Board will meet again on Monday (24 April) to elect the Chair and other appointments. Gareth Jones, Returning Officer for the NPA Board elections, said: "The NPA has undertaken a process of significant modernisation of organisational governance over the past years. Key elements of this process include adopting modern new Articles of Association, reforming the structure of the Board and introducing term limits. The process of electing the Board has also been changed so that half of the Board will be up for election every two years - which supports continuity and reduces the risk of a loss of organisational memory." "Recognising that the Board would already be losing a lot of organisational memory in 2023 with five members of Board standing down, the Board determined that three individuals should be co-opted onto the new Board as the process of transformation continues. In March 2025, anyone that has served 12 years or more will be required to stand down."

The High Court has dismissed the British Generic Manufacturers Association (BGMA)'s claim on being excluded from ongoing negotiations between the government and industry to agree a new Voluntary Scheme for medicine pricing and access (VPAS). The association had sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI) in April. Commenting on the result of the case, Richard Torbett, Chief Executive of the ABPI said: "For over 60 years the ABPI has acted as the representative industry body for negotiations on the Voluntary Scheme for branded medicines - a responsibility we take extremely seriously - and one which has been reaffirmed by today's judgment. "While we were disappointed that the BGMA decided to take this action - we recognise their decision was driven by the extreme challenge placed on all parts of the industry from the surge in the branded medicine payment rates. "The solution to these problems must be a completely new and sustainable approach to medicines provision in the UK which rapidly brings industry revenue payments in line with comparator countries to unlock investment and growth."

Pharmacy professionals to be included as key stakeholders in the implementation, delivery and evaluation of a wide range of genomic services, said the Royal Pharmaceutical Society (RPS). RPS's statement has been developed in collaboration with pharmacy organisations who have co-badged the report, such as the British Oncology Pharmacy Association, the UK Clinical Pharmacy Association, Association of Pharmacy Technicians and the College of Mental Health Pharmacy. It looks at current and future roles for pharmacy professionals in genomic medicine across many aspects of practice such as person-centred care and collaboration, professional practice, education, leadership, management and research. Pharmacists and pharmacy technicians in the UK have already established roles in the application of genomic medicine in some areas of practice, such as antimicrobial stewardship and infectious diseases, and the management of certain genetic conditions, such as cystic fibrosis. The society believes, the current role of pharmacy professionals in genomics can be expanded upon in the future to both lead and support many relevant aspects of genomic implementation. These are described across all healthcare sectors, within the Genome UK strategy produced by the UK Government, and within the implementation plans published in England, Scotland and Wales. Lead for Pharmacogenomics at RPS Sophie Harding said: "Pharmacy professionals are the gatekeepers of medication safety and efficacy across all areas of healthcare. They are skilled at interpreting complex scientific data and use evidence-based medicine to maximise the benefits of treatments for patients, whilst supporting shared decision-making with patients and the multidisciplinary team.

The British Generic Manufacturers Association (BGMA) has sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI). Mark Samuels, Chief Executive of BGMA said: "The Government has decided not to involve the trade body representing these medicine suppliers in its negotiations on the voluntary scheme for branded medicine pricing (VPAS). "We are deeply concerned by this decision. It has left us no choice but to take legal action." "While not all generic drugs fall within VPAS, four out of ten products in the current scheme are branded generics or biosimilars. As the representative trade body for both generic and biosimilar UK manufacturers, we must play a full part in the VPAS negotiations for the next period of the scheme from 2024 to 2028." "The VPAS tax has risen five-fold in under two years, an unprecedented tax increase. Yet our sector currently has no input into the negotiations on future schemes or rates; this is untenable as any decisions made on VPAS could significantly define the future of our sector in the UK and its ability to supply the NHS. The association had raised its full participation in the negotiations with the Government last November.

The leading pharmacy bodies have come together to launch the 'Save Our Pharmacies' campaign which highlights the pressure and untapped potential of the sector. Pharmacy bodies- Association of Independent Multiple Pharmacies (AIMp), Company Chemists' Association (CCA), National Pharmacy Association (NPA) and Pharmaceutical Services Negotiating Committee (PSNC) have agreed to work together on a programme of activities to lobby for fair NHS funding for pharmacies in England, including co-ordinating efforts to mobilise public support. The campaign will focus on highlighting both the pressures that pharmacies are under and the huge untapped potential of the sector - including to offer a Pharmacy First service - if appropriate resourcing is made available. Mark Lyonette, NPA Chief executive, said: "Together we will be cranking up the noise to persuade Government and NHS to make the right choices and back the community pharmacy sector with decent funding. Maintaining patient and public support is critical to our campaigning success, so this will be a key focus in the months ahead. Our joint message is very clear: pharmacies can help get the NHS back on its feet, but not while the sector itself is on its knees." The pharmacy bodies will develop shared resources for effective parliamentary lobbying and mobilising public opinion, in the face of chronic underfunding that threatens further pharmacy closures. They will also work hard to show off the value of pharmacy and to continue pushing for a fully funded Pharmacy First service.